Difficult but Not Impossible: in Search of an Anti-Candida Vaccine

Dillon Piccione 1 · Susanna Mirabelli 1 · Nicholas Minto 1 · Tejas Bouklas 1

Published online: 29 March 2019 © The Author(s) 2019

Abstract

Purpose of Review  Pervasive fungal infection among the immunocompromised population, in conjunction with a lack of effective treatment options, has demanded further scrutiny. Millions of people are still dying annually from fungal infections. While existing treatment for these fungal infections exists, it is difficult to administer without adverse effects in the immunocompromised and is slowly becoming obsolete due to varying mutation rates and rising resistance in multiple species. Thus, vaccines may be a viable target for preventing and treating fungal infections and addressing the critical challenge of such infections.

Recent Findings  Candida albicans, along with other non-albicans Candida species, is among the more virulent class of fungal specimens considered for vaccine development. C. albicans is responsible for a large percentage of invasive fungal infections among immunocompromised and immunocompetent populations and carries a relatively high mortality rate. In the last decade, a recent increase in infective capacity among Candida species has shed light on the lack of adequate fungal vaccine choices. While roadblocks still exist in the development of antifungal vaccines, several novel targets have been examined and proposed as candidates.

Summary  Success in vaccine development has universal appeal; an anti-Candida vaccine formulation could be modified to work against other fungal infections and thus bolster the antifungal pipeline.

Keywords  Candida · Vaccine · Antifungal · Therapy

Introduction

In observing the thousands of fungal species studied, only roughly 600 are associated with fungal infections in humans. These fungal species can have devastating effects on immunocompromised patients, including patients afflicted with HIV and cancer. Nevertheless, there have been cases of outbreaks with fungal diseases in otherwise healthy individuals. There is a family of six dimorphic fungi, which are responsible for roughly one million infections per year [1]. Of these, Cryptococcus and Histoplasma have mortality rates between 20% and 70%, while Candida is slightly higher at 46–75% [2]. Candida species are the fourth most common cause of hospital-acquired infections, and invasive infections often carry a 50% mortality rate despite the use of antifungals. Candida bloodstream infections are estimated to afflict roughly 400,000 patients per year [3].

Vaccines against invasive pathogens represent a major step forward in combating illnesses. Much of the knowledge used to combat bacterial and viral infections has transferred over for use against fungal infections. Regardless of the progress made so far, fungal infections and the treatment used to eliminate them continue to be an area of concern for providers worldwide. The greatest evidence for this can be summarized in the development schedule for effective vaccines. The smallpox vaccine was developed as far back as 1796. The tetanus vaccine followed in 1923, and more vaccines were steadily developed between 1950 and 1998. With the exception of the smallpox vaccine, that roughly correlates to a new vaccine against bacteria or viruses every 10 years. To date, there have been no fungal vaccines cleared for prescription use; however, several experimental models exist.

The Burden and Challenge of Candidiasis

Candida albicans and non-albicans Candida (NAC) species, Candida glabrata, Candida parapsilosis, and Candida

This article is part of the Topical Collection on Tropical Mycoses

Tejas Bouklas
tejas.bouklas@liu.edu

1 Department of Biomedical Sciences, Long Island University-Post, Brookville, NY, USA

© Springer
Published online: 29 March 2019
tropicalis are natural commensals and less common as pathogens. However, all species can become opportunistic pathogens in immunocompromised populations, including transplant recipients, or individuals receiving chemotherapy and other cancer medications. Patients with central lines are exceptionally at risk, as Candida species are responsible for roughly 12% of all central line infections [4]. Likewise, neonatal patients are susceptible to infections due to their immature immune system. According to a data set from a National Inpatient Survey in 2000, candidemia correlated to an additional 10.1 days of stay, resulting in an additional $40,000 in costs per patient. Hospitalization in infants proved even worse with an extra 21-day stay correlating to an extra $92,000+ in extra costs [4].

Roadblocks in the development of more modern treatments are common and involve a sharp decline in research, as well as a lack of incentive towards antifungal development. Development of antifungals, in comparison to medications that treat chronic conditions, often requires a high cost for a low rate of return. In the last 13 years, the FDA has approved only five antifungal agents, which can be categorized within the two classes of echinocandins (caspofungin, micafungin, and anidulafungin) and triazoles (voriconazole and posaconazole) [4]. Posaconazole is a newly approved generation of azoles that has a higher proven efficacy compared to the early-generation azoles, such as fluconazole and itraconazole. Caspofungin, micafungin, and anidulafungin are progressive generations of echinocandins.

An additional challenge is posed by the widespread distribution and emergence of new Candida strains. Population-based studies suggest that the distribution of C. albicans to NAC species varies by region. Blood samples taken have shown that C. albicans is mostly prevalent in the USA and Northern and Central Europe. The NAC species discussed in this review include C. glabrata found mostly in Northern and Central Europe [3], C. parapsilosis in Slovakia, Southern Europe, South America, and Asia [5], and C. tropicalis in the Asia-Pacific region [3]. Importantly, emerging multidrug resistant NAC species, such as Candida auris, are found in India, South Africa, South America, North America, and Europe [6]. Geographical distribution of other NAC species is available [7] but not discussed.

To resolve the burden and challenges posed by candidiasis and similar mycoses, current and promising antifungal therapies must be developed to be used in immunocompromised populations, who often show the most adverse effects and whose immune systems do not cooperate with chemotherapy. Due to their status, the immunocompromised may become gravely ill even from innocuous vaccines. It is because of this caveat that development of an anti-Candida vaccine seems less feasible. In this patient population, passive immunization has now emerged as a promising alternative to treat disseminated mycosis [8]. Also of interest is the use of antibodies to neutralize infections without induction of a memory response. What follows is a discussion of ongoing and potential efforts in the development of an anti-Candida therapy.

**Current Candida Immunogenic Targets and Vaccination Efforts**

A summary of current and potential targets discussed below to various Candida species (Table 1) and pathogenic fungi in general (Table 2) is also provided.

**C. albicans**

Antifungal therapies involve targeting specific molecular entities, such as the cell wall or ribosomal transcription, in pathogenic fungi. Current treatment for C. albicans includes the medication fluconazole, which inhibits lanosterol 14α-demethylase, leading to the inhibition of ergosterol synthesis in the endoplasmic reticulum [4]. Live samples of the infective agent have been used as an alternative to the conventional antifungal treatment. Several live attenuated samples of C. albicans have been tested, including genetically engineered CNC13 and PCA-2 strains. While it has been found that these strains offer some protection against lethal infection in the laboratory, none of have progressed to clinical trials [3].

Agglutin-like sequence (Al)s proteins are an area of study to inhibit growth of C. albicans by means of blocking fungal cell adhesion, invasion, and biofilm formation. One study involving recombinant Als1 demonstrated a 50–57% increased survival in mice models [9]. Als proteins have also served as a target for successful monoclonal antibody binding. Growth of immunolabeled C. albicans strains shows a vast presence of Als3. The antibodies, 113 and 3-A5, were able to block C. albicans from adhering to endothelial and buccal cell surfaces at specific concentrations. Likewise, these antibodies studied showed specificity for C. albicans against other fungal species [10]. Other protein targets tested include the heat shock protein 90 (Hsp90). Heat shock proteins are released in the cell to protect against extremely high temperatures. Mice models treated with a recombinant Hsp90 vaccine (r-hsp90-CA) showed a 118% survival rate compared to the control when infected with C. albicans [9].

Progression towards antifungal vaccines has not been limited to protein targets. Certain carbohydrate entities have shown varied success in suppressing C. albicans growth. Laminarin (Lam) is a β-glucan entity isolated from brown algae. When conjugated to the diphtheria toxoid, CRM197, it has been shown to suppress C. albicans growth. β-glucan is a vital component of fungal cell membranes. Studies have shown that Lam-CRM binds non-uniformly to C. albicans hyphae as well as some septal regions. This binding had led to a decrease in fungal burden [12•].
Much like antibacterial therapy, gene targets have also been used to suppress C. albicans growth. The hyphae gene, HYR1, has been implicated in reduced phagocytosis of C. albicans. Studies involving this gene include a recombinant protein product, similar to the aforementioned heat shock proteins. Immunization with this protein has shown increased survival against C. albicans infections, with the effect greater when both alleles of HYR1 were silenced [13]. Lastly, the enzyme enolase (Eno1p) has been implicated as a viable vaccine option. Subcutaneous and intramuscular injections of the Eno1p vaccine in mice infected with a lethal dose of C. albicans showed survival rates of 12.5–25% [29].

**C. glabrata**

C. glabrata, while not a leading pathogen in humans, is nonetheless prevalent in adults [3]. Much like C. albicans, it can be found in our oral and GI tract. Upon immunosuppression, it can cause widespread infection. Echinocandins, most commonly used to treat infection with C. glabrata, inhibit β-D-glucan synthetase, an enzyme that functions in cell wall synthesis. In vitro and in vivo studies with the investigational drug, isavuconazole, have suggested efficacy against several Candida species, including C. glabrata.

More novel vaccination options for C. glabrata include the use of cobalt 3 (Co III) coordination complexes. Cobalt complexes function as chelating agents, drawing away vital cofactor ions that fungal enzymes need to function. In a study involving several Candida species, C. glabrata had the most sensitive MIC and MHC ranges for cobalt treatment. The study concluded that this was due to its inability to form hyphae [14].

Mannoproteins in the cell wall of C. glabrata and C. albicans have similarly been considered as targets. The molecule used against them is mannose-binding lectin (MBL), a protein that is synthesized in the liver and involved in complement cascade activation. Investigations of its function have found MBL-induced agglutination in the yeast

### Table 1

Summary of current and potential vaccine targets to *Candida* species discussed in the review

| Species                  | Current or potential therapy targets                                      | Reference(s) |
|--------------------------|---------------------------------------------------------------------------|--------------|
| *C. albicans, C. tropicalis* | Genetically engineered strains, CNC13 and PCA-2                           | [4]          |
| *C. albicans, C. glabrata*  | Agglutinin-like sequence (Als) proteins, 113, 3A-5                        | [9, 10]      |
| *C. albicans*             | Recombinant heat shock protein, r-hsp90-CA                                | [9, 11]      |
| *C. albicans*             | Laminarin, CRM197                                                         | [12]         |
| *C. albicans, C. glabrata* | HYR1                                                                      | [3, 13]      |
| *C. glabrata*             | Cobalt complexes                                                          | [14]         |
| *C. glabrata*             | Mannose-binding lectin                                                    | [15]         |
| *C. parapsilosis*         | Histadin-5                                                                | [16]         |
| *C. parapsilosis*         | Experimental vaccine (NDV-3)                                              | [17, 18]     |
| *C. parapsilosis, C. tropicalis* | Plant based: *Eugenia dysenterica, Pouteria ramiflora, Ocotea odorifera* | [16]         |
| *C. tropicalis*           | Plant based: *Lonicera japonica, thymol*                                  | [19]         |
| *C. albicans*             | PKC inhibitors, cercosporamide, staurosporine                             | [20]         |
| *C. albicans*             | Human lactoferrin, hLF1-11                                                | [16, 21]     |
| *C. albicans*             | Phage vaccine                                                             | [22]         |

### Table 2

Summary of potential cross protective targets to various pathogenic fungi discussed in the review

| Potential therapy targets                                                                 | Reference(s) |
|------------------------------------------------------------------------------------------|--------------|
| Genetically engineered strains: CNC13 and PCA-2                                           | [4]          |
| Agglutinin-like sequence (Als) proteins: 113, 3A-5                                        | [9, 10]      |
| Recombinant heat shock proteins: r-hsp90-CA                                              | [9, 11]      |
| Laminarin: CRM197                                                                         | [12]         |
| Replicative aging                                                                         | [23–25]      |
| Respiratory pathways: Mir1                                                                  | [26]         |
| Sphingolipid metabolism: BHBM, D13                                                        | [27]         |
| Micafungin activated metacaspase complexes                                                 | [28]         |
| Tricyclic antidepressants                                                                  | [16]         |
| Genetically engineered organisms: *Lactobacillus casei* containing the Eno1p antigen       | [29]         |
phase to treat both *C. glabrata* and *C. albicans*. This was achieved through binding to the mannoproteins covering the fungal cell surface, inducing complement activation [15•]. *C. glabrata* possesses the *HYR1* mannoprotein on the surface of its hyphae. By using a recombinant version of its N terminus, the vaccine was found effective in animal models challenged against a lethal dose of *C. glabrata* [3]. The Als class of proteins were found to be viable targets for *C. albicans* vaccine efforts. An intriguing result is that recombinant Als1 has been found to be similarly effective against *C. glabrata*. In fact, this species lacks Als proteins and does not typically form hyphae unless incorporated into the aggregates initiated by *C. albicans* [30]. The interactions of *C. glabrata* and *C. albicans*, which lead to cell-to-cell aggregation, may be important in understanding the pathogenesis of *C. glabrata*. This may also be a valid explanation for the effectiveness of recombinant Als1 in this species incapable of hyphal formation. This also begs further investigation into this class of proteins against other non-hyphae-forming fungal species as an alternative treatment option.

**C. parapsilosis**

*C. parapsilosis* is an organism implicated in many nosocomial infections. The current preferred pharmacological treatment of *C. parapsilosis* targets ergosterol inhibition, such as fluconazole. Patients who cannot tolerate this medication are given amphotericin B in either a regular or lipid formulation [4]. *C. parapsilosis* is an organism implicated in many nosocomial infections. By using a recombinant version of its N terminus, the vaccine was found effective in animal models challenged against a lethal dose of *C. glabrata* [3]. The Als class of proteins were found to be viable targets for *C. albicans* vaccine efforts. An intriguing result is that recombinant Als1 has been found to be similarly effective against *C. glabrata*. In fact, this species lacks Als proteins and does not typically form hyphae unless incorporated into the aggregates initiated by *C. albicans* [30]. The interactions of *C. glabrata* and *C. albicans*, which lead to cell-to-cell aggregation, may be important in understanding the pathogenesis of *C. glabrata*. This may also be a valid explanation for the effectiveness of recombinant Als1 in this species incapable of hyphal formation. This also begs further investigation into this class of proteins against other non-hyphae-forming fungal species as an alternative treatment option.

*Another commonly used drug is flucytosine, which inhibits thymidylate synthetase, an enzyme associated with nucleic acid synthesis. Metabolism of this drug may subsequently interfere with translation via accumulation of 5-fluorodeoxyuridine monophosphate [16]. Because of differences in its cell wall structure, *C. parapsilosis* produces high amounts of inflammatory cytokines. Even if further studies are required to know more about the cell wall composition of *C. parapsilosis*, by observing lectin staining, chitin exposure can be analyzed. Peripheral blood mononuclear cells (PBMCs) are responsible for the underlying mechanism for producing higher levels of pro-inflammatory cytokines due to the deletion of the α1,6-mannosyltransferase. Blocking of cell surface receptors, such as TLR4 and β-glucans, has been shown to decrease its virulence [31]. An alternative mode of antifungal treatment against *C. parapsilosis* involves the use of antifungal peptides. Histadin-5, which is found in saliva and interferes with ATP efflux in fungal cells, has been shown to produce high fungicidal activity at low concentrations [16]. Several investigated plant models, including Eugenia dyserenterica and Pouteria ramiflora, have exhibited comparable potent activity against *C. parapsilosis* with low MIC values. Additionally, ellagitannins isolated from Ocotea odorifera, a plant commonly used in Brazilian folk medicine, provide excellent activity against *C. parapsilosis* [16]. Als sequences are once again implicated as viable targets when treating infections with *C. parapsilosis*. Als3 has been used to develop an experimental vaccine, NDV-3. Phase I studies have found that NDV-3 induces strong B and T cell responses to candidiasis and is generally well tolerated. Furthermore, B and T cell responses increased when exposed to additional NDV-3 doses [17•].

**C. tropicalis**

*C. tropicalis* infections are commonly associated in patients with neutropenia and malignancy [3]. Current treatment options include polyenes, triazoles, and echinocandins. Resistance to flucytosine has been noted in this species and is not considered for treatment [32•]. This limits targets to its cell wall and cell membrane. Unfortunately, *C. tropicalis* has developed multiple resistance mechanisms. Mutations in the ERG11 gene have conferred azole resistance and in the FKS1 gene to echinocandins.

Given the already limited scope of prescription therapy, the search for alternative treatments is expected. Extracts from the Chinese plant, *Lonicera japonica*, exhibited strong antifungal activity, anti-inflammatory cytokines, and potent wound healing capacity [19]. Likewise, the plants *E. dysenterica* and *P. ramiflora* also showed strong activity. Thymol is a constituent of essential oils from thyme that has been shown to possess antifungal properties. It measured an MIC value of 78 μg/mL against *C. tropicalis* [19].

Live attenuated *C. albicans* has been shown to provide non-specific cross protection against subsequent challenge with virulent *C. albicans* in mice. Specifically, the protection was observed by injecting mice with an avirulent strain and by macrophage-like cells, whereby adoptive transfer of “plastic adherent” cells also provided protection. Cross protection against *C. tropicalis* and *Staphylococcus aureus* was comparably observed (studies summarized in [3]). Further, isavuconazole has been shown to be active in vitro against NAC species, including *C. tropicalis*. This drug is currently in Phase III testing stage. Albacozal was equally effective; however, it is only in Phase II [4].

**C. auris**

Due to an increase in antimicrobial use, strains of *Candida auris* have emerged that are resistant to most conventional treatments. One such species, *C. auris*, was identified in 2009. A major concern with *C. auris* for specific patient populations is biofilm formation on implanted devices, such as peripherally inserted central catheter (PICC) lines or central arterial lines. Removal of these devices is of utmost importance. Patient resistance to at least one antifungal often helps identify...
C. auris. However, it presents additional barriers to treatment because it is often misidentified as other yeasts. It is unique from other strains of Candida in that it can be more readily transmitted between patients in hospitals and the environment. Its rapid identification of the organism is often one of the most important aspects of proper treatment.

Most cases in the USA have been treated with echinocandins since most of identified strains have been susceptible to them. Patients are sometimes be followed up with broad-spectrum antibiotics for treatment. Combination therapy, while widely used in treating resistant bacterial infections, has been less explored in treating resistant antifungal infections. Regardless, certain combination antifungal therapies have been developed along with new formulations, such as liposomal Ambisome [16].

Alternative strategies may target fungal stress response regulators. Hsp90 protects the cell from extreme temperatures, while calcineurin acts as a protein phosphatase. Evolutionary studies suggest that altering these targets enhances the effects of azoles and makes them more fungicidal [11]. Further investigation into cell stress targets revealed that these stress signals function as part of a protein kinase C (PKC) signaling pathway. PKC has been shown to regulate cell wall integrity in Candida spp. Cercosporamide is a selective Pkc1 inhibitor and can be purified from the fungus Cercosporidium henningsii. Additional PKC inhibitors include staurosporine. Furthermore, combination therapy of cercosporamide with micafungin displayed synergistic activity against a previously resistant strain of C. albicans [20*].

Human lactoferrin is a peptide found in humans that functions to hydrolyze RNA molecules and may be a potential solution for emergent species. It has been shown to assist in clearing infections, as well as stimulating dendritic cells and macrophages. Studies show that human lactoferrin 1-11 (hLF1-11) also inhibited C. albicans biofilm formation at early stages through the Ras-cAMP-Efg1 pathway, interfering with biofilm cellular density and metabolic activity [16]. The potential of this protein as a stand-alone treatment is evident but more interesting in conjunction with existing antifungal therapy. In fact, this synergistic approach may enable a lowering of the standard antymycotic intake required by existing therapy [21]. Further studies will need to be done to establish efficacy of the combination therapy, especially in a clinical setting. However, this approach seems worthy of consideration.

**Potential Candida Immunogenic Targets**

Increasing incidence of resistance to antifungals, in conjunction with parallel evolutionary development with humans, has prompted the search for vaccine targets. The NDV-3A vaccine has recently announced positive Phase II results and uses the Als3 surface protein as a vaccine target [18].

Fungal aging, a more novel area of research that looks into the microevolution of the pathogen, has also demonstrated potential for an antifungal vaccine. Studies in Cryptococcus neoformans and C. glabrata have demonstrated that the cell wall undergoes changes with the age of the cell [23, 24]. Additional observations revealed that phenotypic switching can lower the number of replications that daughter cells undergo compared to the parent cell. Hypothetically, a vaccine that induces increased phenotypic switching rates could increase the effectiveness of existing antifungals. This difference in aging has even been documented in the emergent species, C. auris [25].

Respiratory pathways in fungal pathogens are an emerging field of experimentation when it comes to vaccine development. Mirl1 is a protein required for respiration in Saccharomyces cerevisiae. Its requirement for Candida species has not been extensively studied; however, the ML316 probe used against mitochondrial phosphate transport exhibited more potent fungicidal activity against azole resistant Candida [26*]. Nevertheless, many fungi are facultative aerobes and may still persist in anaerobic environments if needed.

Another novel approach that has gained traction is sphingolipid metabolism. In a study conducted with the synthetic drug, BHBM, an assay showed dose-dependent killing of C. neoformans. Mice subjects treated with BHBM and its derivative D13 survived after infection with live C. albicans [27]. Research into this avenue of fungal vaccination is one of the first to clear Phase II trials.

Medications and vaccines that cause direct death of the cell run the risk of increasing mutations to favor additional resistance mechanisms in the pathogen. Candida species can evade the humoral immune response by secreting Sap9 and Sap10 to inactivate antimicrobial peptides. They have also developed ways to attach phase inhibitors of the complement cascade to their outer wall and avoid complement activation [34]. In addition, they can proliferate and form hyphae within macrophages and lyse the cells [35].

Potentially, a well-designed vaccine would cause the cell to die of its own volition, perhaps by altering its apoptotic pathway. In this scenario, the vaccine would signal the cell that it is non-functional when, in reality, it is viable. The delivery method of this vaccine would require evasion of host immune response, likely by encasement in a lipid endosome. In a study involving micafungin-activated metacaspase complexes, the antifungal increased reactive oxygen species, lowered mitochondrial membrane potential, and activated metacaspase activity in caspofungin susceptible and non-susceptible C. albicans and C. parapsilosis [28]. The major drawback to this therapy is that micafungin is a foreign molecule, and thus the fungal cell may recognize this and develop resistance mechanisms, such as efflux pumps or inactivating enzymes.
Unconventional treatment options may need to be considered. Studies suggest that tricyclic antidepressants can not only kill *C. albicans* hyphae and inhibit biofilm formation but also kill mature *Candida* residing in biofilms [16]. Additionally, using genetically engineered organisms, which are benign to the host but lethal to the invading pathogen, is another potential avenue. *Lactobacillus casei* modified with a HPV16 E7 molecular display and a *Streptococcus pyogenes* M6 anchor protein have been shown to confer immunity to human papillomavirus in mice models. When tested with *C. albicans*, *L. casei* containing the Eno1p antigen generated seven times more antibodies compared to a control [29].

The aforementioned design can be applied to using phages against fungal infection. Mice inoculated with a recombinant phage containing a peptide from fructose biphosphate aldolase induced humoral and cellular immune responses and relieved kidney damage in mice with candidiasis [22]. Similar phage models are used in gene therapy to treat patients with genetic diseases, such as cystic fibrosis. While this may provide some relief of symptoms, constant administration is needed.

**Critical Challenges and Future Directions**

*C. albicans* has coevolved with humans for at least the past 2000 years. Not surprisingly, this has led to the development of several host immune evasion mechanisms, including high genetic, phenotypic, and morphological plasticity [3]. Since *C. albicans* can switch phenotypically, identification of the organism during infection may be delayed. Gross variations of *Candida* species colonization can be observed across different geographical regions, making a targeted vaccine approach difficult. Within the last decade, *C. auris* has also identified itself as a threat, specifically because it is multidrug resistant and difficult to rapidly identify. Both *C. auris* and *C. albicans* also form biofilms, which further increase resistance to antifungal treatment. NAC species, such as *C. glabrata*, show extensive azole resistance, have been identified in candidemia infections, and would therefore benefit from vaccine development.

A viable vaccine for *Candida* has the potential to contribute to the antifungal pipeline [36], specifically by widening the search for vaccines against other fungal infections responsible for high mortality. *Aspergillus fumigatus* causes chronic pulmonary disease in about three million people per year and can carry a wide range of mortality [2]. It can also form Rod A, a resistance mechanism that diminishes the ability of neutrophils to phagocytose fungal cells [34]. *C. neoformans*, much like *C. albicans*, can form biofilms. *C. neoformans* affects patients worldwide and has mortality rates as high as 70%. It has a capsule and can form large bodies called titan cells, which allows it to evade key immune cells and prevents it from being phagocytosed easily [34]. Ultimately, *C. neoformans* would similarly benefit from the development of a functional vaccine.

Of particular interest to the antifungal pipeline is the development of antibodies to neutralize an infection without inducing an active immune response. The human recombinant antibody against Hsp90, Mycograb®, already shows synergistic activity in combination with amphotericin B [37]; it would be worth investigating its application to other fungal pathogens, including *Aspergillus* spp. and *C. neoformans*, both of which possess Hsp90. With the same logic, the monoclonal antibodies IgM(B6.1) and IgG3(C3.1) made against the β1,2-mannotriose epitope of *C. albicans* could be used for passive immunotherapy [38]. These have an established protective role in a murine infection model. The killer toxin discussed in this review, among others [39], is also an option for passive immunotherapy [40]. Lastly, the IgG2a WGA-Fc, which binds to chitin, is among a line of universal vaccine candidates [41].

Clearly, there are several areas being investigated in the race to develop a viable FDA-approved antifungal vaccine. Despite this, vaccine efforts are costly and require years of research and multiple phase testing to be cleared. Further, vaccine development for *Candida* species comes with the challenge of dealing with an immunosuppressed patient population, as well as showing efficacy against constantly evolving and multidrug-resistant organisms. While this review showcases several developments towards an anti-*Candida* vaccine, ideally the most promising candidates will (1) include multivalent fungal antigens that divert potential risk, (2) protect against several fungal pathogens, and (3) combine antifungal drugs and immunostimulants. Ultimately, fungal infections pose a serious illness and require further novelty and persistence in the race to vaccine development. But because the finish line can now be seen, it is time to prioritize and bolster these developments.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

Papers of particular interest, published recently, have been highlighted as:

- Of importance

1. Thompson DS, Carlisle PL, Kadosh D. Coevolution of morphology and virulence in Candida species. Eukaryot Cell. 2011;10(9):1173–82. https://doi.org/10.1128/EC.05085-11.
2. Pal M. Morbidity and mortality due to fungal infections. J Appl Microbiol Biotechnol 2017;1(1). doi:https://doi.org/10.21767/2576-1412.100002.

3. Tso GHW, Reales-Calderon JA, Pavelka N. The elusive anti-Candida vaccine: lessons from the past and opportunities for the future. Front Immunol. 2018;9. https://doi.org/10.3389/fimmu.2018.00897.

4. Moriyama B, Gordon LA, McCarthy M, Henning SA, Walsh TJ, Penzak SR. Emerging drugs and vaccines for candidemia. Mycoses. 2014;57(12):718–33. https://doi.org/10.1111/myc.12265.

5. Sanguinetti M, Postero B, Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses. 2015;58(S2):2–13. https://doi.org/10.1111/myc.12330.

6. Lockhart SR, Berkw EL, Chow N, Welsh RM. Candida auris for the clinical microbiology laboratory: not your grandfather’s Candida species. Clin Microbiol NewsL. 2017;39(13):99–103. https://doi.org/10.1016/j.clinmicnews.2017.06.003.

7. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20(Suppl 6):5–10. https://doi.org/10.1111/1469-0691.12539.

8. Garcia-Carnero LC, Perez-Garcia LA, Martinez-Alvarez JA, Reyes-Martinez JE, Mora-Montes HM. Current trends to control fungal pathogens: exploiting our knowledge in the host-pathogen interaction. Infect Drug Resist. 2018;11:903–13. https://doi.org/10.2147/IDR.S170337.

9. X-j W, Sui X, Yan L, Wang Y, Y-b C, Y-y J. Vaccines in the treatment of invasive candidiasis. Virulence. 2015;6(4):309–15. https://doi.org/10.4161/viru.36884.2014.983015.

10. Coleman DA, Oh S-H, Zhao X, Zhao H, Hutchins JT, Vernachio JH, et al. Monoclonal antibodies specific for Candida albicans Als3 that immobilized fungal cells in vitro and in vivo and blocked adhesion to host surfaces. J Microbiol Methods. 2009;78(1):71–8. https://doi.org/10.1016/j.mimet.2009.05.002.

11. Hill JA, Ammar R, Torti D, Nislow C, Cowen LE. Genetic and genomic architecture of the evolution of resistance to antifungal drug combinations. PLoS Genet. 2013;9(4):e1003390. https://doi.org/10.1371/journal.pgen.1003390. Genomic analysis of several fungal lineages revealed mechanisms responsible for multidrug resistance. Azole resistance via efflux pump and chaperone inactivating substances were identified, which may provide scientists with an idea of how these resistance mechanisms evolve in pathogenic fungi.

12. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med. 2005;202(5):597–606. https://doi.org/10.1084/jem.20050749. Exposure of glucan entities on the fungal cell surface was shown to confer a degree of protection against Candida sp. in previous studies. Therefore, models with beta-glucan conjugated to a strong immunogenic target (diphtheria toxoid) can potentially serve as a vaccine against the pathogen.

13. Luo G, Ibrahim AS, Spellberg B, Nobile CJ, Mitchell AP, Fu Y. Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis. 2010;201(11):1718–28. https://doi.org/10.1086/652407. The HYR1 gene in fungal species mediates phagocytic resistance via alteration of anchorage proteins on the fungal surface. Hence, disruption of this gene sequence is a potential target for vaccine development and phagocytosis enhancement in systemic candidiasis.

14. Turecka K, Chylewska A, Kawiak A, Waleron KF. Antifungal activity and mechanism of action of the Co (III) coordination complexes with diamine chelate ligands against reference and clinical strains of Candida spp. Front Microbiol. 2018;9. https://doi.org/10.3389/fmicb.2018.01594.

15. Hammad NM, El Badawy NE, Grahm HA, Al Kady LM Mannose-binding lectin: a potential therapeutic candidate against Candida infection. Biomed Res Int (2018) Mannose-binding lectin (MBL) is used by the immune system to identify many pathogens including fungal pathogens. Studies on fungal exposure to MBL indicate an increase in agglutination of the pathogen, suggesting that MBL may be used in conjunction with other treatments to slow the infective process of pathogenic fungi.

16. Caldara M, Marmiroli N. Tricyclic antidepressants inhibit Candida albicans growth and biofilm formation. Int J Antimicrob Agents. 2018;52(4):500–5. https://doi.org/10.1016/j.ijantimicag.2018.06.023.

17. Schmidt CS, White CJ, Ibrahim AS, Filler SG, Yu Y, Yeaman MR, et al. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus is safe and immunogenic in healthy adults. Vaccine. 2012;30(52):7594–600. https://doi.org/10.1016/j.vaccine.2012.10.038. Vaccine in phase I studies of NDV-3 induced a heightened production of IgA1 and IgG antibodies in approximately 70% of subjects tested. NDV-3 was likewise well-tolerated will little to no side effects.

18. Positive Phase 2 results of Novadigm TX’s NDV-3A vaccine published in Clinical Infectious Diseases. EurekAlert!

19. de Oliveira Santos GC, Vasconcelos CC, Lopes AJO, de Sousa Cartágenses M, Filho AKDB, do Nascimento FR, et al. Candida infections and therapeutic strategies: mechanisms of action for traditional and alternative agents. Front Microbiol. 2018;9:1351. https://doi.org/10.3389/fmicb.2018.01351.

20. SF LF, Collins C, Zaas AK, Schell WA, Betancourt-Quiroz M, Gunatilaka AAL, et al. PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog. 2010;6(8):e1001069. https://doi.org/10.1371/journal.ppat.1001069. Inhibition of protein kinase C (PKC) in Candida albicans induces hypersensitivity to antifungals to which the organism was originally resistant against. Inhibition of PKC likewise affects downstream signaling to additional entities (Hsp90), which may indicate a potential target for anti-fungal compounds outside of those traditionally used.

21. Kuipers ME, de Vries HG, Eikleboom MC, Meijer DJ, Swart PJ. Synergistic fungicidal effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob Agents Chemother. 1999;43(11):2635–41.

22. Shi H, Dong S, Zhang X, Chen X, Gao X, Wang L. Phage vaccines displaying YGKDVKDLDFYAQEE epitope induce protection against systemic candidiasis in mouse model. Vaccine. 2018;36(38):5717–24. https://doi.org/10.1016/j.vaccine.2018.08.011.

23. Bouklas T, Alonso-Crisostomo L, Szekely T Jr, Diago-Navarro E, Orner EP, Smith K, et al. Generation of a Candida glabrata population: resilient old cells prevail, while younger cells originally resistant against. Inhibition of PKC likewise affects downstream signaling to additional entities (Hsp90), which may indicate a potential target for anti-fungal compounds outside of those traditionally used.

24. Bouklas T, Alonso-Crisostomo L, Szekely T Jr, Diago-Navarro E, Orner EP, Smith K, et al. Generation of a Candida glabrata population: resilient old cells prevail, while younger cells originally resistant against. Inhibition of PKC likewise affects downstream signaling to additional entities (Hsp90), which may indicate a potential target for anti-fungal compounds outside of those traditionally used.
This may pose as an alternative to common treatments, which negatively affect the host.

27. Lazzarini C, Haranahalli K, Rieger R, Ananthula HK, Desai PB, Ashbaugh A, et al. Acylhydrazones as antifungal agents targeting the synthesis of fungal sphingolipids. Antimicrob Agents Chemother. 2018;62(5). https://doi.org/10.1128/AAC.00156-18.

28. Shirazi F, Kontoyiannis DP. Micafungin triggers caspase-dependent apoptosis in Candida albicans and Candida parapsilosis biofilms, including caspofungin non-susceptible isolates. Virulence. 2015;6(4):385–94. https://doi.org/10.1080/21505594.2015.1027479.

29. Shibasaki S, Karasaki M, Tafuku S, Aoki W, Sewaki T, Ueda M. Oral immunization against candidiasis using Lactobacillus casei displaying enolase 1 from Candida albicans. Sci Pharm. 2014;82(3):697–708. https://doi.org/10.3797/scipharm.1404-07.

30. Klotz SA, Gaur NK, De Armond R, Sheppard D, Khardori N, Edwards JE Jr, et al. Candida albicans Als proteins mediate aggregation with bacteria and yeasts. Med Mycol. 2007;45(4):363–70. https://doi.org/10.1080/13693780701299333.

31. Snarr BD, Qureshi ST, Sheppard DC. Immune recognition of fungal polysaccharides. J Fungi (Basel). 2017;3(3). https://doi.org/10.3390/jof3030047.

32. Lilly EA, Ikeh M, Nash EE, Fidel PL, Noverr MC. Immune protection against lethal fungal-bacterial intra-abdominal infections. mBio. 2018;9(1). doi:https://doi.org/10.1128/mBio.01472-17. It is suggestive from this experiment that inoculation with Candida species can induce protection against organisms, including Candida albicans and Staphylococcus aureus.

33. Romo JA, Pierce CG, Esqueda M, Hung C-Y, Saville SP, Lopez-Ribot JL. In vitro characterization of a biaryl amide anti-virulence compound targeting Candida albicans filamentation and biofilm formation. Front Cell Infect Microbiol. 2018;8. https://doi.org/10.3389/fcimb.2018.00227 The Biaryl Amide compound investigated in this study induced resistance to fungal filamentation and biofilm formation. The compound is currently found to work in Candida albicans, C. dubliniensis, and C. tropicalis.

34. Hernández-Chávez MJ, Pérez-García LA, Niño-Vega GA, Mora-Montes HM. Fungal strategies to evade the host immune recognition. J Fungi (Basel). 2017;3(4):51. https://doi.org/10.3390/jof3040051.

35. Marcos CM, de Oliveira HC, de Melo WCMA, da Silva JF, Assato PA, Scorzoni L, et al. Anti-immune strategies of pathogenic fungi. Front Cell Infect Microbiol. 2016;6:142. https://doi.org/10.3389/fcimb.2016.00142.

36. Denning DW, Bronley MJ. Infectious disease. How to bolster the antifungal pipeline. Science. 2015;347(6229):1414–6. https://doi.org/10.1126/science.aaa0697.

37. Matthews RC, Burnie JP. Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine. 2004;22(7):865–71. https://doi.org/10.1016/j.vaccine.2003.11.032.

38. Yuan RR, Spira G, Oh J, Paizi M, Casadevall A, Scharff MD. Isotype switching increases efficacy of antibody protection against Cryptococcus neoforms infection in mice. Infect Immun. 1998;66(3):1057–62.

39. Polonelli L, Morace G. Production and characterization of yeast killer toxin monoclonal antibodies. J Clin Microbiol. 1987;25(2):460–2.

40. Magliani W, Conti S, Salati A, Vaccari S, Ravanetti L, Maffei DL, et al. Therapeutic potential of yeast killer toxin-like antibodies and mimotopes. FEMS Yeast Res. 2004;5(1):11–8. https://doi.org/10.1016/j.femsyr.2004.06.010.

41. Liedke SC, Miranda DZ, Gomes KK, Goncalves JLS, Frases S, Nosanchuk JD, et al. Characterization of the antifungal functions of a WGA-Fc (IgG2a) fusion protein binding to cell wall chitin oligomers. Sci Rep. 2017;7(1):12187. https://doi.org/10.1038/s41598-017-12540-y.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.